Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 67

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 67
---
 the option of the holder, the holder may convert the Series E Preferred Stock at the “Alternate Optional Conversion Price” equal to the lesser of: •The applicable Conversion Price, and •the greater of: •the floor price of $1.00 (the “Floor Price”); and •95% of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. 36 Alternate Conversion Upon a Triggering Event.Following the occurrence and during the continuance of a Triggering Event (as defined below), each holder may alternatively elect to convert the Series E Preferred Stock at the “Alternate Triggering Event Conversion Price” (and together with the Alternate Optional Conversion Price, each an “Alternate Conversion Price”) equal to the lesser of: •The applicable Conversion Price, and •the greater of: •the Floor Price; and •90% of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. The Certificate of Designations contains standard and customary triggering events (each, a “Triggering Event”), including but not limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S -1or Form S -3pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the Company’s intention not to comply with a request for conversion of any Series E Preferred Stock, and (iv) bankruptcy or insolvency of the Company. Other Adjustments.In connection with the Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stockholders, of the issuance of Conversion Shares at a conversion price below the Conversion Price (the date of such approval, the “Stockholder Approval Date”). If the Company has not otherwise obtained such stockholder approval prior to October 31, 2025, which is not expected to occur, then the Company shall (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC no later than October 31, 2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than November 30, 2025 and (iii) use reasonable best efforts to hold the Stockholder Meeting no later than December 31, 2025 (the “Stockholder Meeting Deadline